| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | EVP, R&D and CSO | Common Stock, $0.01 par value | 42.3K | $8.67M | $205.02 | Feb 28, 2025 | Direct |
| AbbVie Inc. | EVP, R&D and CSO | Option (Right to buy) | 25K | $2.34M | $93.50 | Feb 13, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | Feb 28, 2025 | 1 | -$959K | 4 | Mar 4, 2025 | EVP, R&D and CSO |
| ABBV | AbbVie Inc. | Feb 13, 2025 | 5 | $0 | 4 | Feb 18, 2025 | EVP, R&D and CSO |
| ABBV | AbbVie Inc. | Feb 28, 2024 | 1 | -$880K | 4 | Mar 1, 2024 | SVP, CMO, GLOBAL THERAPEUTICS |
| ABBV | AbbVie Inc. | Feb 15, 2024 | 5 | $0 | 4/A | Feb 7, 2025 | EVP, R&D and CSO |
| ABBV | AbbVie Inc. | Dec 14, 2023 | 0 | $0 | 3 | Dec 22, 2023 | SVP, Global Therapeutics & CMO |